• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Impact of low sodium values on survival outcomes of patients with cancer receiving immune checkpoint inhibitors.低钠值对接受免疫检查点抑制剂治疗的癌症患者生存结局的影响。
Immunotherapy. 2024;16(12):821-828. doi: 10.1080/1750743X.2024.2370231. Epub 2024 Jul 17.
2
Impact of comorbidity on immune-related adverse events and survival in older cancer patients treated with immunotherapy.合并症对接受免疫治疗的老年癌症患者免疫相关不良事件和生存的影响。
Future Oncol. 2025 Jun;21(14):1787-1796. doi: 10.1080/14796694.2025.2502313. Epub 2025 May 27.
3
Prognostic value of serum albumin-creatinine ratio as a biomarker in patients treated with immune checkpoint inhibitors.血清白蛋白-肌酐比值作为免疫检查点抑制剂治疗患者生物标志物的预后价值
Immunotherapy. 2025 Jun;17(8):567-575. doi: 10.1080/1750743X.2025.2513850. Epub 2025 Jun 5.
4
Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study.癌症类型和组织学影响皮肤免疫治疗的毒性：一项多机构队列研究。
Br J Dermatol. 2024 Jun 20;191(1):117-124. doi: 10.1093/bjd/ljae053.
5
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
6
Effect of systemic glucocorticoid immunosuppression timing, dose, and duration on overall survival among immune checkpoint inhibitor recipients: a retrospective multicohort study.全身糖皮质激素免疫抑制的时机、剂量和持续时间对免疫检查点抑制剂接受者总生存的影响：一项回顾性多队列研究
medRxiv. 2025 Jun 23:2025.06.23.25330022. doi: 10.1101/2025.06.23.25330022.
7
Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer.免疫检查点抑制剂联合铂类化疗对比铂类化疗联合或不联合贝伐珠单抗用于治疗老年人晚期非小细胞肺癌的一线治疗。
Cochrane Database Syst Rev. 2024 Aug 13;8(8):CD015495. doi: 10.1002/14651858.CD015495.
8
Characterizing Thyroid Hormone Replacement, Baseline Thyrotropin, and Survival in Immune Checkpoint Inhibitor-Associated Thyroid Dysfunction.免疫检查点抑制剂相关甲状腺功能障碍中甲状腺激素替代、基线促甲状腺激素与生存情况的特征分析
Thyroid. 2025 Jun 18. doi: 10.1089/thy.2025.0076.
9
Albumin-myosteatosis gauge as a prognostic biomarker in patients treated with immune checkpoint inhibitors.白蛋白-肌脂肪变性指标作为接受免疫检查点抑制剂治疗患者的预后生物标志物。
Immunotherapy. 2025 Jun 27:1-9. doi: 10.1080/1750743X.2025.2525743.
10
Validating Khorana Risk Score in gastric cancer patients on immune checkpoint inhibitors and chemotherapy.验证胃癌患者接受免疫检查点抑制剂和化疗时的科拉纳风险评分。
Immunotherapy. 2025 Apr;17(6):419-424. doi: 10.1080/1750743X.2025.2501922. Epub 2025 May 7.

引用本文的文献

1
Temporal Trends of Hyponatremia in Patients with Respiratory and Intrathoracic Cancers Treated with Chemotherapy and Immune Checkpoint Inhibitors.接受化疗和免疫检查点抑制剂治疗的呼吸及胸内癌症患者低钠血症的时间趋势
Cancers (Basel). 2025 Apr 26;17(9):1459. doi: 10.3390/cancers17091459.
2
Commentary: Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study.评论：骨转移的肾透明细胞癌患者的钠水平与免疫治疗疗效：Meet-Uro 15研究的亚组分析
Front Immunol. 2024 Nov 7;15:1476215. doi: 10.3389/fimmu.2024.1476215. eCollection 2024.

本文引用的文献

1
Low geriatric nutritional risk index as a poor prognostic biomarker for immune checkpoint inhibitor treatment in solid cancer.低老年营养风险指数作为实体癌免疫检查点抑制剂治疗不良预后的生物标志物
Front Nutr. 2023 Nov 1;10:1286583. doi: 10.3389/fnut.2023.1286583. eCollection 2023.
2
Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab.纳武利尤单抗治疗转移性肾细胞癌患者的血清钠水平与结局。
JAMA Netw Open. 2023 Nov 1;6(11):e2345185. doi: 10.1001/jamanetworkopen.2023.45185.
3
Effects of nutritional indices and inflammatory parameters on patients received immunotherapy for non-small cell lung cancer.营养指标和炎症参数对接受免疫治疗的非小细胞肺癌患者的影响。
Curr Probl Cancer. 2024 Feb;48:101035. doi: 10.1016/j.currproblcancer.2023.101035. Epub 2023 Nov 20.
4
Hyponatremia and malnutrition: a comprehensive review.低钠血症与营养不良：全面综述。
Ir J Med Sci. 2024 Apr;193(2):1043-1046. doi: 10.1007/s11845-023-03490-8. Epub 2023 Sep 13.
5
Hyponatraemia and the syndrome of inappropriate antidiuresis (SIAD) in cancer.癌症中的低钠血症和抗利尿激素分泌失调综合征（SIAD）
Endocr Oncol. 2022 Jul 11;2(1):R78-R89. doi: 10.1530/EO-22-0056. eCollection 2022 Jan.
6
Adrenal Metastasectomy in the Era of Immuno- and Targeted Therapy.免疫治疗和靶向治疗时代的肾上腺转移瘤切除术。
Ann Surg Oncol. 2023 Jul;30(7):4146-4155. doi: 10.1245/s10434-023-13474-8. Epub 2023 Apr 20.
7
Prevalence and Prognostic Significance of Hyponatremia in Patients With Lung Cancer: Systematic Review and Meta-Analysis.肺癌患者低钠血症的患病率及预后意义：系统评价与Meta分析
Front Med (Lausanne). 2021 Dec 7;8:671951. doi: 10.3389/fmed.2021.671951. eCollection 2021.
8
Hyponatremia as a prognostic factor in non-small cell lung cancer: a systematic review and meta-analysis.低钠血症作为非小细胞肺癌的预后因素：一项系统评价和荟萃分析。
Transl Lung Cancer Res. 2021 Feb;10(2):651-661. doi: 10.21037/tlcr-20-877.
9
Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors.接受免疫检查点抑制剂治疗的患者的低钠血症和其他电解质异常。
Nephrol Dial Transplant. 2021 Dec 2;36(12):2241-2247. doi: 10.1093/ndt/gfaa272.
10
Epidemiology of Brain Metastases.脑转移瘤的流行病学。
Neurosurg Clin N Am. 2020 Oct;31(4):481-488. doi: 10.1016/j.nec.2020.06.001.

低钠值对接受免疫检查点抑制剂治疗的癌症患者生存结局的影响。

Impact of low sodium values on survival outcomes of patients with cancer receiving immune checkpoint inhibitors.

机构信息

Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE.

Ankara University, Cancer Research Institute, Ankara 06620, TÜRKİYE.

出版信息

Immunotherapy. 2024;16(12):821-828. doi: 10.1080/1750743X.2024.2370231. Epub 2024 Jul 17.

DOI:10.1080/1750743X.2024.2370231
PMID:39016058
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11457628/
Abstract

Low serum sodium affects cancer prognosis, but its impact on immunotherapy is unclear. Assessing the association of pre- and post-ICI treatment sodium levels with survival. We retrospectively analyzed patients receiving ICI in January 2012-December 2023, collecting serum sodium levels at treatment initiation and 4 weeks post-ICI, with overall survival (OS) as the primary outcome. Low sodium was observed in 125 and 119 patients pre-and post-treatment respectively. Pre-ICI and post-ICI low sodium correlated with decreased OS [10.6 vs. 22.9 months ( = 0.001) and 11.6 vs. 27.2 months ( = 0.009)]. Multivariate analysis identified pre-ICI low sodium [HR: 1.685; 95% CI: 1.050-2.705; = 0.031] as an independent risk factor for worse OS. Low baseline serum sodium was an independent risk factor for poor OS in patients treated with ICIs.

摘要

低血清钠会影响癌症预后，但它对免疫疗法的影响尚不清楚。评估ICI 治疗前和治疗后钠水平与生存的关系。我们回顾性分析了 2012 年 1 月至 2023 年 12 月期间接受 ICI 治疗的患者，收集治疗开始时和 ICI 治疗后 4 周的血清钠水平，以总生存期（OS）作为主要结局。治疗前和治疗后分别有 125 名和 119 名患者出现低钠血症。ICI 前和 ICI 后低钠血症与降低的 OS 相关[10.6 个月 vs. 22.9 个月（ = 0.001）和 11.6 个月 vs. 27.2 个月（ = 0.009）]。多变量分析确定 ICI 前低钠血症[HR：1.685；95%CI：1.050-2.705； = 0.031]是 OS 较差的独立危险因素。低基线血清钠是接受 ICI 治疗的患者不良 OS 的独立危险因素。